# tables/ADA/adat04b.qmd result_v1 stable

    Code
      print(data_snap[[i]])
    Output
      Baseline Prevalence and Incidence of Neutralizing Antibodies (NAbs)
      Protocol: A: Drug X Antibody
      
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
                                                           A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
                                                            (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Baseline Prevalence of NAbs                                                                                          
        Baseline evaluable patients for ADA                   134           132             0           0           266    
        Patients with a positive ADA sample at baseline       63             64             0           0           127    
        Patients with a positive NAb sample at baseline        0             0              0           0            0     
        Patients with no positive NAb sample at baseline       0             0              0           0            0     
      Incidence of NAbs                                                                                                    
        Post-baseline evaluable patients for ADA              134           132             0           0           266    
        Patients positive for ADA                             66             59             0           0           125    
        Patients positive for NAb                              0             0              0           0            0     
        Patients negative for NAb                             134           132             0           0           266    
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      
      NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s) Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s) Post-baseline evaluable patient for ADA = a patient with an ADA assay result from at least one post-baseline sample Post-baseline evaluable patient for NAb = a patient with a NAb assay result from at least one post-baseline sample Number of patients positive for ADA = the number of post-baseline evaluable patients for ADA determined to have Treatment Emergent ADA during the study period.
      Number of patients positive for NAb = the number (and percentage) of post-baseline evaluable patients for ADA determined to have at least one positive post-baseline NAb result during the study period. Number of patients negative for NAb = number of post-baseline evaluable patients with all negative post-baseline NAb results.

